Introduction of Biosimilars could Make Competition in Global HER2 Antibodies Market More Intense

Human epidermal growth factor receptor 2 (Her2) is an oncogene whose amplification or over-expression is mostly associated with the chances of developing an aggressive type of breast cancer. The American Cancer Society observes that nearly 15-30% of cases of breast cancer has an amplified Her2 gene. Her2 antibodies are reported to make the tumor worse by interrupting oncogenic signals and/or triggering Fc receptor-mediated cytotoxicity. The area of Her2 antibodies is witnessing a vast rise in attention from pharmaceutical companies over the recent past as the patient pool of breast cancer continues to rise at an alarming pace across the globe.

Transparency Market Research, in one of its recent market research reports, estimates that the global HER2 antibodies market will expand at an impressive 8.6% CAGR from 2017 to 2025. At this pace, the market could rise substantially up from a valuation of US$10,087.8 mn in 2016 to an opportunity of US$21,669.1 mn by 2025.

In this blog post, Transparency Market Research analysts highlight some of the key trends in the global HER2 antibodies market:

Which regional market presents most promising growth opportunities for the HER2 antibodies market?

From a geographical perspective, the North America market is currently the leading revenue generator and is also the leading contributor of new product varieties to the global market. The presence of some of the world’s leading companies and the high rate of incidence of breast cancer in the region contribute to its leading position in the global market. Other factors such as favorable reimbursement policies and high disposable incomes of the population make HER2 antibody treatment within the means of patients in the region.

North America is expected to remain a highly lucrative regional market for HER2 antibodies in the next few years as well, with new drug categories and biosimilars expected to fuel uptake. Europe is also expected to remain one of the leading revenue contributors to the global HER2 antibodies market owing to high disposable incomes and favorable medical insurance scenario.

How competitive is the global HER2 antibodies market?

The competitive landscape of the global HER2 antibodies market is intense owing to the presence of a large number of contributors with presence in both regional as well as global space. Companies are competing for opportunities in the breast cancer and personalized medicine segments and are expected to invest increased sums in research and development activities to strengthen their hold on the competitive market. Companies are also focusing on growth opportunities across less-developed regional markets to benefit from untapped opportunities. As a result, instances of mergers, acquisitions, and collaborations of international companies with regional players have increased and will rise in the near future as well.

Patent expiry of tratuzumab (Herceptin), one of the most widely prescribed HER2 antibody drug for breast cancer, in the European market in mid-2014 has led to the introduction of a number of biosimilars, further intensifying the level of competition in the market. While Roche continues to own the patent for the drug in the U.S. market until 2019, it has also introduced new drugs such as Perjeta and TDM-1, Kadcyla and has established a good control on the global HER2 antibodies market.


Post a Comment

Note: only a member of this blog may post a comment.

Latest Post

Market Research Reports